Zanubrutinib Plus Obinutuzumab Elicits Improved Responses in Relapsed/Refractory Follicular Lymphoma
June 8th 2022The addition of zanubrutinib to obinutuzumab in patients with relapsed/refractory follicular lymphoma demonstrated improved overall response rates, progression-free survival, and overall survival.
Read More
Dostarlimab monotherapy induced durable antitumor activity in advanced or recurrent endometrial cancer among patients with mismatch repair deficient/microsatellite instability–high or mismatch repair proficient/mismatch stable disease, according to data from 2 expansion cohorts in the GARNET trial.
Read More
LUMINA Study Revels Radiotherapy is Not Needed for Some Luminal A Breast Cancers
June 7th 2022According to Timothy J. Whelan, MD, FASCO, radiotherapy is an inconvenient treatment. It can last daily for up to 5 weeks and it is a costly therapy. Study results shows that is can safely be omitted in the treatment of some patients with luminal A breast cancers.
Read More
FOLFOXIRI Plus Bevacizumab Shows Positive Efficacy But Increased Toxicity in CRC Liver Metastases
June 7th 2022Phase 3 CAIRO5 showed improvements in progression-free survival and overall response with FOLFOXIRI plus bevacizumab in colorectal cancer liver metastases, but the combination demonstrated a toxic safety profile.
Read More
Risk Factors Linked to Discontinuation of Adjuvant Abemaciclib in HR+/HER– Breast Cancer
June 6th 2022Several key risk factors seen in the monarchE trial of adjuvant abemaciclib could help early monitoring of patients with hormone receptor–positive, HER2-negative, node-positive high-risk early breast cancer to prevent discontinuation.
Read More
Brain Metastasis in Patients With NSCLC Correlates With Enrichment of CDKN2A/B and EGFR Mutations
June 6th 2022Correlations between non–small cell lung cancer the metastasizes to the brain and enriched CDKN2A/B and EGFR alterations calls for further genomic exploration of this patient population.
Read More
Patients with NSCLC Experience Improved DFS with Pembrolizumab After Surgery
June 6th 2022Adjuvant pembrolizumab led to improved disease-free survival versus placebo in patients with fully resected non–small cell lung cancer, according to second interim results from the PEARLS/KEYNOTE-091 trial.
Read More
Frontline Bevacizumab Beneficial for Ovarian Clear Cell Carcinoma, Retrospective Analysis Shows
June 6th 2022Bevacizumab improved progression-free survival and overall survival when added to frontline chemotherapy in patients with advanced ovarian clear cell carcinoma, according to a retrospective analysis of patients treated in Japan from 2008 to 2018.
Read More
Adding Pembrolizumab Extends OS and PFS in Key Subgroups in Recurrent, Metastatic Cervical Cancer
June 6th 2022Results from the KEYNOTE-826 trial showed that chemotherapy plus pembrolizumab with or without bevacizumab improved overall survival and progrssion-free survival in patients with metastatic cervical cancer based on subgroups including histology and prior treatment type.
Read More
NSCLC With Baseline Brain Metastases Predictive of Limited Benefit from Mobocertinib
June 6th 2022In patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer that has progressed after mobocertinib treatment, remaining on mobocertinib may be warranted, according to news research.
Read More